𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of interteron α2β monotherapy with the combination of thymosin α1 and interferon α2b in the treatment of anti-HBe-postive chronic hepatitis B in turkey

✍ Scribed by Saruc, Murat; Yuceya, Hakan; Kucukmetin, Nurten; Demir, Mehmet A.; Kandiloglu, Ali R.


Book ID
124147259
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
190 KB
Volume
120
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Long-term outcomes of thymosin-α1 and in
✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and

Cost effectiveness of interferon α2b com
✍ Zobair M. Younossi; Mendel E. Singer; John G. McHutchison; Kenneth M. Shermock 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

## Treatment of chronic hepatitis C with Interferon (IFN) ␣2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated